Wegovy 1.7mg vs Mounjaro: The Complete Treatment Guide
Can I Start Wegovy at 1.7mg Versus Mounjaro: Understanding Your Options
The decision of whether you can start Wegovy at 1.7mg versus choosing Mounjaro depends on your clinical history and prescriber assessment. Wegovy 1.7mg represents the penultimate dose in the escalation protocol, typically prescribed for weeks 13-16 after successful titration from lower doses. Mounjaro, containing tirzepatide, offers a different mechanism as a dual GIP and GLP-1 receptor agonist, compared to Wegovy's single GLP-1 pathway. Your prescriber will evaluate factors including previous tolerability, weight management goals, and individual response patterns. The choice between these prescription-only medicines requires careful clinical consideration rather than direct dose-to-dose comparison.
When considering "can I start Wegovy at 1.7mg" against Mounjaro alternatives, timing and treatment history become crucial factors. Wegovy's structured escalation from 0.25mg ensures optimal tolerability, making direct initiation at 1.7mg clinically inappropriate for treatment-naive patients. Mounjaro follows its own titration schedule, starting at 2.5mg and escalating differently than Wegovy's pathway. Both medications require prescription assessment and cannot be interchanged without proper medical evaluation. EverydayMeds stocks both options, allowing your prescriber flexibility in choosing the most suitable treatment approach for your individual circumstances.
Wegovy 1.7mg Pricing and Mounjaro Cost Comparison
Wegovy 1.7mg costs £139.99 at EverydayMeds, positioning it competitively within the weight management prescription market. Our Elevate Duo bundle combines 1.7mg with 2.4mg maintenance dosing for £369.99, providing seamless progression without supply interruption. Returning customers can apply code DOSE25 at checkout, while new customers benefit from FIRST40 for optimal pricing. The Consistency 1.7mg bundle offers two pens for £309.99, ideal for extended treatment at this crucial escalation phase.
Mounjaro pricing follows a different structure due to its distinct dosing protocol and longer titration schedule. When evaluating "can I start Wegovy at 1.7mg" versus Mounjaro options, consider the total treatment cost including escalation phases and maintenance requirements. Both medications require ongoing prescription assessment and cannot be purchased without proper clinical evaluation. EverydayMeds' transparent pricing eliminates hidden fees, with all costs including prescriber review and next-day cold-chain delivery to maintain medication integrity.
Clinical Evidence: Wegovy 1.7mg Versus Mounjaro Research
The STEP trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved significant weight management outcomes, with STEP 1 showing approximately 15% average weight loss at 68 weeks. Wegovy 1.7mg represents a critical phase where many participants experienced accelerating results before reaching 2.4mg maintenance. The SELECT cardiovascular outcomes trial further established a 20% reduction in major cardiovascular events with semaglutide treatment. These findings support the structured escalation approach that makes starting directly at 1.7mg clinically inappropriate.
Mounjaro's clinical evidence stems from the SURMOUNT trial series, demonstrating tirzepatide's dual receptor mechanism in weight management contexts. Direct comparison between STEP and SURMOUNT outcomes requires careful interpretation due to different study designs and patient populations. When considering "can I start Wegovy at 1.7mg" against Mounjaro, your prescriber will evaluate individual clinical factors rather than population-level trial data. Both medications show promising results when used alongside reduced-calorie diet and increased physical activity as part of comprehensive weight management programmes.
How Wegovy 1.7mg Works Compared to Mounjaro Mechanism
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural incretin hormones responsible for appetite regulation and glucose homeostasis. At 1.7mg dosing, semaglutide provides near-maximal GLP-1 receptor activation, promoting satiety signals and reducing food cravings through central nervous system pathways. The medication slows gastric emptying, extending feelings of fullness after smaller meal portions. Mounjaro's tirzepatide offers dual GIP and GLP-1 receptor agonism, potentially providing additional metabolic benefits through the glucose-dependent insulinotropic polypeptide pathway. Both mechanisms require gradual dose escalation to optimise tolerability and therapeutic response, explaining why direct initiation at higher doses isn't recommended.
Ordering Process for Wegovy 1.7mg and Mounjaro
EverydayMeds streamlines access to both Wegovy 1.7mg and Mounjaro through our 3-minute online clinical assessment portal. Our GPhC-registered prescribers (#9012878) review applications within standard 3 working days, with express 24-hour options available for urgent requirements. Once approved, both medications ship via next-day cold-chain delivery maintaining the crucial 2-8°C temperature range. The assessment covers medical history, current medications, and treatment objectives to determine suitability for either option. Our clinical team ensures appropriate dose selection, making direct Wegovy 1.7mg initiation only available for patients with documented escalation history.
Storage and Practical Considerations: Wegovy vs Mounjaro
Wegovy offers superior storage flexibility with 6 weeks room temperature stability once removed from refrigeration, compared to Mounjaro's 21-day limit below 30°C. Both medications require initial refrigerated storage at 2-8°C and use pre-filled pen injection systems for weekly administration. The FlexTouch pen design for Wegovy provides consistent dosing accuracy, while maintaining cold-chain integrity during transport ensures medication potency. For patients asking "can I start Wegovy at 1.7mg", understanding storage requirements becomes crucial for treatment adherence and travel planning. Proper handling protocols apply equally to both medications, with EverydayMeds providing comprehensive storage guidance with every delivery.
Advanced Dose Selection: When 1.7mg Wegovy Versus Mounjaro Makes Sense
The question "can I start Wegovy at 1.7mg" typically arises for patients transitioning from other treatments or those with specific clinical circumstances requiring careful dose selection. Prescribers may consider this dose for patients with documented semaglutide experience or those switching from alternative weight management medications. The 1.7mg phase represents optimal preparation for 2.4mg maintenance, allowing assessment of response patterns before final dose escalation. Mounjaro's different escalation schedule means equivalent therapeutic positioning occurs at different timepoints and dose levels.
Treatment-experienced patients might find Wegovy 1.7mg offers the ideal balance between therapeutic effect and tolerability as they approach maintenance therapy. The Elevate Duo bundle specifically addresses this transition phase, providing both 1.7mg and 2.4mg doses for seamless progression. Mounjaro patients following their own escalation protocol will have different transition considerations based on tirzepatide's unique pharmacology. Both pathways require individualised prescriber assessment to ensure optimal treatment outcomes.
Secure Your Wegovy 1.7mg or Mounjaro Treatment Today
EverydayMeds provides comprehensive access to both Wegovy 1.7mg at £139.99 and Mounjaro alternatives through our secure prescription platform. Returning customers can apply code DOSE25 at checkout for continued competitive pricing, while new patients benefit from FIRST40 for initial orders. Our clinical assessment ensures appropriate medication selection whether you're asking "can I start Wegovy at 1.7mg" or considering Mounjaro alternatives. Begin your assessment at https://everydaymeds.co.uk/collections/weight-loss for professional prescriber review and next-day delivery. Both medications represent significant advances in weight management therapy when used alongside reduced-calorie diet and increased physical activity under proper medical supervision.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
